| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | 172 | 29.489 | 245.026 | 428.562 | 716.445 | 1.885.222 | 1.138.117 | 478.597 | 1.555 |
| Total Income - EUR | - | 5.758 | 29.562 | 245.259 | 449.582 | 770.951 | 1.890.459 | 1.408.985 | 561.438 | 188.938 |
| Total Expenses - EUR | - | 101.297 | 145.727 | 230.922 | 463.779 | 777.539 | 1.545.562 | 1.348.293 | 605.319 | 271.711 |
| Gross Profit/Loss - EUR | - | -95.539 | -116.165 | 14.337 | -14.197 | -6.588 | 344.898 | 60.692 | -43.881 | -82.773 |
| Net Profit/Loss - EUR | - | -95.544 | -116.460 | 11.886 | -18.555 | -13.659 | 316.664 | 51.140 | -43.881 | -82.773 |
| Employees | - | 4 | 4 | 2 | 5 | 9 | 19 | 15 | 9 | 2 |
Check the financial reports for the company - Pfane Scientific S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | 112.357 | 94.830 | 79.694 | 106.885 | 152.779 | 204.913 | 566.940 | 528.663 | 341.374 |
| Current Assets | - | 46.319 | 81.332 | 93.332 | 278.778 | 152.059 | 769.289 | 234.392 | 218.680 | 184.005 |
| Inventories | - | 11.406 | 14.700 | 71.366 | 125.339 | 0 | 52.628 | 20.790 | 72.608 | 72.760 |
| Receivables | - | 26.287 | 48.022 | 6.408 | 195.100 | 121.566 | 462.424 | 166.365 | 109.947 | 93.774 |
| Cash | - | 8.627 | 18.609 | 15.558 | -41.661 | 30.493 | 254.238 | 47.236 | 36.126 | 17.471 |
| Shareholders Funds | - | -95.455 | -210.299 | -194.554 | -209.342 | -219.032 | 102.489 | 153.947 | 89.696 | 6.422 |
| Social Capital | - | 89 | 88 | 86 | 84 | 83 | 81 | 81 | 81 | 80 |
| Debts | - | 254.132 | 386.461 | 367.581 | 595.005 | 523.871 | 871.713 | 647.384 | 657.648 | 518.958 |
| Income in Advance | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "3821 - 3821" | |||||||||
| CAEN Financial Year |
3831
|
|||||||||
Comments - Pfane Scientific S.r.l.